FMP

FMP

Enter

ABIO - ARCA biopharma, Inc.

Financial Summary of ARCA biopharma, Inc.(ABIO), ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes geneti

photo-url-https://financialmodelingprep.com/image-stock/ABIO.png

ARCA biopharma, Inc.

ABIO

NASDAQ

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.

3.25 USD

0.02 (0.615%)

About

ceo

Dr. Michael R. Bristow M.D., Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.arcabio.com

exchange

NASDAQ

Description

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorad...

CIK

0000907654

ISIN

US00211Y5069

CUSIP

00211Y506

Address

10170 Church Ranch Way

Phone

720 940 2200

Country

US

Employee

4

IPO Date

Aug 8, 1997

Summary

CIK

0000907654

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

00211Y506

ISIN

US00211Y5069

Country

US

Price

3.25

Beta

1.21

Volume Avg.

1.43M

Market Cap

47.13M

Shares

-

52-Week

1.56-3.88

DCF

2.58

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-8.78

P/B

-

Website

https://www.arcabio.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest ABIO News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep